We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| OSE Immunotherapeutics | EU:OSE | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.05 | 0.71% | 7.06 | 7.03 | 7.15 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 7.25 | 7.01 | 7.01 | 67,623 | 13:05:00 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 18/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2.. |
| 18/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de .. |
| 11/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage.. |
| 11/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®,.. |
| 04/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits.. |
| 02/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité.. |
| 02/12/2024 | 17:00 | UKREG | OSE Immunotherapeutics Strengthens Leadership and Executive Committee |
| 04/11/2024 | 17:00 | UKREG | Informations relatives au nombre total de droits de vote et d’actions.. |
| 04/11/2024 | 06:30 | UKREG | OSE Immunotherapeutics Announces Statistically Significant and Clinically.. |
| 04/11/2024 | 06:30 | UKREG | OSE Immunotherapeutics Annonce des Résultats Cliniquement Probants et.. |
1 Year OSE Immunotherapeutics Chart |
Intraday OSE Immunotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
